| [1] |
Zhang B, Beeghly-Fadiel A, Long J, et al. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence[J].Lancet Oncol,2011,12(5):477-488.
|
| [2] |
Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management [J]. Mol Oncol,2009,3(2):97-137.
|
| [3] |
van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer [J]. Cell Oncol (Dordr), 2011,34(2):71-88.
|
| [4] |
Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian [J]. MedGenMed, 2005,7(2):60.
|
| [5] |
Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma [J].Cancer,2013,119(2):332-338.
|
| [6] |
Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes--risk and response[J].J Mammary Gland Biol Neoplasia,2011,16(1):3-15.
|
| [7] |
Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers[J]. JAMA, 2008, 299(2):194-201.
|
| [8] |
Palma MD, Domchek SM, Stopfer J, et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families[J].Cancer Res,2008,68(17):7006-7014.
|
| [9] |
Anczuków O, Buisson M, Léoné M, et al. BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy[J]. Clin Cancer Res,2012,18(18):4903-4909.
|
| [10] |
Brewster BL, Rossiello F, French JD, et al. Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site[J]. Hum Mutat,2012,33(12):1665-1675.
|
| [11] |
Risch HA, McLaughlin JR, Cole DE, et al.Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada[J]. J Natl Cancer Inst,2006,98(23):1694-1706.
|
| [12] |
Metcalfe KA,Poll A,Royer R. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women[J]. J Clin Oncol,2010,28(3):387-391.
|
| [13] |
Laraqui A, Uhrhammer N, Lahlou-Amine I, et al. Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population[J]. Int J Med Sci,2013,10(1):60-67.
|
| [14] |
Weitzel JN, Clague J, Martir-Negron A, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network[J].J Clin Oncol,2013,31(2):210-216.
|
| [15] |
Lara K,Consigliere N, Pérez J, et al. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela[J]. Biol Res,2012,45(2):117-130.
|
| [16] |
Kwong A,Ng EK,Wong CL,et al. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis[J]. PLoS One,2012,7(9):e43994.
|
| [17] |
胡震,邵志敏. 中国遗传性乳腺癌研究经验浅析[J/CD].中华乳腺病杂志:电子版,2011,5(3):350-355.
|
| [18] |
陈丽芬,耿翠芝,王桂兰, 等. 河北省家族性和散发性乳腺癌易感基因1/2 突变的研究[J/CD]. 中华乳腺病杂志:电子版,2010,4(4):418-426.
|
| [19] |
Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome [J]. Oncogene, 2008,27(41):5387-5397.
|
| [20] |
Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models[J]. Nat Rev Cancer,2007,7(1):35-45.
|
| [21] |
Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation[J]. Hum Mol Genet, 1998,7(3):507-515.
|
| [22] |
Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway[J].Am J Hum Genet,2003,73(2):404-411.
|
| [23] |
Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations[J]. Clin Cancer Res,2012,18(2):400-407.
|
| [24] |
Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes [J].Eur J Hum Genet,2008,16(11):1289-1300.
|
| [25] |
Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations[J].J Clin Endocrinol Metab,2011,96(12):E2063-2071.
|
| [26] |
Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview[J].Genet Med,2009,11(10):687-694.
|
| [27] |
Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features[J]. J Med Genet,2011,48(8):505-512.
|
| [28] |
Chompret A, Brugières L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals[J].Br J Cancer,2000,82(12):1932-1937.
|
| [29] |
Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome[J]. J Natl Cancer Inst,1998,90(8):606-611.
|
| [30] |
Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers[J].Cancer Epidemiol Biomarkers Prev,2001,10(2):83-87.
|
| [31] |
Smeenk G, de Groot AJ, Romeijn RJ, et al. Rad51C is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability[J]. Mutat Res,2010,689(1-2):50-58.
|
| [32] |
Clague J, Wilhoite G, Adamson A, et al. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families[J]. PLoS One,2011,6(9):e25632.
|
| [33] |
Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene [J]. Nat Genet, 2010,42(5):410-414.
|
| [34] |
De Leeneer K, Van Bockstal M, De Brouwer S, et al.Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing[J]. Breast Cancer Res Treat, 2012, 133 (1):393-398.
|
| [35] |
Johnson J, Healey S, Khanna KK, et al. Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families[J]. Breast Cancer Res Treat, 2011,129(1):255-263.
|
| [36] |
Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research[J]. J Med Genet,2010,47(7):436-444.
|
| [37] |
Caldeira JR, Prando EC, Quevedo FC, et al. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer[J]. BMC Cancer,2006,6:48.
|
| [38] |
Sproul D, Nestor C, Culley J, et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer[J]. Proc Natl Acad Sci U S A,2011,108(11):4364-4369.
|
| [39] |
Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice [J]. Gastric Cancer,2010,13(1):1-10.
|
| [40] |
Guilford P, Hopkins J,Harraway J,et al. E-cadherin germline mutations in familial gastric cancer[J]. Nature, 1998, 392(6674):402-405.
|
| [41] |
Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer[J]. Am J Hum Genet,2002,71(2):432-438.
|
| [42] |
Wong MW, Nordfors C, Mossman D, et al. BRIP1, PALB2,and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer[J]. Breast Cancer Res Treat,2011,127(3):853-859.
|
| [43] |
Cantor SB, Bell DW, Ganesan S, et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function[J]. Cell,2001,105(1):149-160.
|
| [44] |
Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles[J]. Nat Genet, 2006, 38(11):1239-1241.
|
| [45] |
Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene[J]. Nat Genet,2007,39(2):165-167.
|
| [46] |
Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer[J]. Nat Rev Cancer,2006,6(4):259-269.
|
| [47] |
Ratner E, Lu L, Boeke M, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk[J]. Cancer Res,2010,70(16):6509-6515.
|
| [48] |
Paranjape T, Heneghan H, Lindner R, et al. A 3′-untranslated region KRAS variant and triple-negative breast cancer:a case-control and genetic analysis[J]. Lancet Oncol,2011,12(4):377-386.
|
| [49] |
Knudson AG. Two genetic hits (more or less) to cancer[J].Nat Rev Cancer,2001,1(2):157-162.
|
| [50] |
Manoukian S, Verderio P, Tabano S, et al. X chromosome inactivation pattern in BRCA gene mutation carriers[J]. Eur J Cancer,2013,49(5):1136-1141.
|
| [51] |
Feliubadaló L, Lopez-Doriga A, Castellsagué E, et al. Nextgeneration sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes[J].Eur J Hum Genet,2013,21(8):864-870.
|
| [52] |
Michils G, Hollants S, Dehaspe L, et al. Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using ampliconbased massive parallel pyrosequencing[J].J Mol Diagn,2012,14(6):623-630.
|
| [53] |
Saito M, Matsuzaki M, Sakuma T, et al. Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS[J]. Breast Cancer,2014,21(2):140-145.
|
| [54] |
Amir E, Freedman OC, Seruga B, et al. Assessing women at high risk of breast cancer: a review of risk assessment models[J].J Natl Cancer Inst,2010,102(10):680-691.
|
| [55] |
Bellcross CA, Lemke AA, Pape LS, et al. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population[J]. Genet Med, 2009,11(11):783-789.
|
| [56] |
Biswas S, Tankhiwale N, Blackford A, et al. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO[J]. Breast Cancer Res Treat,2012,133(1):347-355.
|
| [57] |
CottChubiz JE, Lee JM, Gilmore ME, et al. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers[J]. Cancer,2013,119(6):1266-1276.
|
| [58] |
King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial[J]. JAMA,2001,286(18):2251-2256.
|
| [59] |
Kim J, Oktay K. Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? [J].Cancer Causes Control,2013,24(3):421-426.
|
| [60] |
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group [J]. J Clin Oncol,2004,22(6):1055-1062.
|
| [61] |
Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: longterm experiences at the Rotterdam Family Cancer Clinic[J].Ann Surg Oncol,2007,14(12):3335-3344.
|
| [62] |
Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers[J]. J Natl Cancer Inst,1999,91(17):1475-1479.
|
| [63] |
Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study [J]. J Clin Oncol,2005,23(30):7491-7496.
|
| [64] |
Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study [J]. Lancet Oncol,2006,7(3):223-229.
|
| [65] |
Zbuk K, Xie C, Young R, et al. BRCA2 variants and cardiovascular disease in a multi-ethnic study [J]. BMC Med Genet,2012,13:56.
|
| [66] |
Daemen A, Wolf DM, Korkola JE, et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib[J]. Breast Cancer Res Treat, 2012,135(2):505-517.
|
| [67] |
Clark CC, Weitzel JN, O’ Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor,and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models[J]. Mol Cancer Ther,2012,11(9):1948-1958.
|
| [68] |
Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial[J].Breast Cancer Res Treat,2012,133(3):1067-1075.
|
| [69] |
Danza K, Pilato B, Lacalamita R, et al. Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer[J].Eur J Hum Genet,2013,21(8):824-830.
|
| [70] |
Weidong L, Shuling W, Xiaojing G, et al. Nipple involvement in breast cancer: retrospective analysis of 2323 consecutive mastectomy specimens[J]. Int J Surg Pathol, 2011,19(3):328-334.
|